Co-Inventors
Zhao, Min
Huang, Liang-Min
Xia, Ning-Shao
Graham, Barney
McLellan, Jason
Kwong, Peter
Chen, Man
Therapeutic Areas
Respiratory
Infectious Disease
The development of 5C4, a monoclonal antibody targeting the prefusion conformation of the Respiratory Syncytial Virus (RSV) Fusion (F) glycoprotein, represents a significant advancement in RSV vaccine research. Unlike the postfusion state, the prefusion conformation of the F glycoprotein contains unique epitopes targeted by neutralizing antibodies. 5C4 was discovered through screening hybridomas for antibodies that neutralized the virus but did not bind to a stabilized form of postfusion F, with 5C4 exhibiting approximately 50-fold higher neutralizing activity than the licensed monoclonal antibody palivizumab (Synagis). Further characterization revealed 5C4's specificity for the prefusion conformation of the F glycoprotein, with binding sites identified at residues 60-75 and 200-212. The atomic-level crystal structure of the RSV F glycoprotein in the prefusion conformation in complex with 5C4 elucidated the unique antigenic site targeted by potent neutralizing antibodies like 5C4.
Commercial Applications
The potential applications of 5C4 extend beyond RSV vaccine development, with implications for both preventive and therapeutic interventions. As a highly potent neutralizing antibody, 5C4 could be incorporated into novel RSV vaccine formulations aimed at enhancing immune responses, especially in high-risk populations such as infants and the elderly. Additionally, 5C4's specificity for the prefusion conformation of the RSV F glycoprotein makes it a promising candidate for passive immunotherapy, offering immediate protection against RSV infection in vulnerable individuals. Furthermore, 5C4's ability to compete with other antibodies targeting the prefusion F trimer suggests its utility as a research tool for studying RSV pathogenesis and immune responses, potentially leading to new insights and therapeutic strategies for combating RSV-
Competitive Advantages
5C4 stands out in RSV vaccine development due to its exceptional potency, surpassing palivizumab by approximately 50-fold. Its specificity for the prefusion conformation of the RSV F glycoprotein, targeting unique epitopes at residues 60-75 and 200-212, enhances its efficacy and safety profile. 5C4's competitive advantage is further demonstrated by its ability to compete with antibodies targeting the apex of the prefusion F trimer, showcasing its versatility in immune response studies. These attributes position 5C4 as a promising candidate for advancing RSV immunotherapy and vaccine strategies.
